bsd1 Antibody

What is BSD1 and what is its biological significance?

BSD1 (BSD domain-containing protein 1) is a transcription factor involved in important regulatory pathways, particularly in plant biology. Research indicates that BSD1 plays a crucial role in the SINA1-BSD1 module that controls vegetative growth in plants. This occurs through direct and indirect regulation of gene expression, particularly genes involved in growth hormone biosynthesis. BSD1 functions as a transcription factor that can directly activate target genes by binding to specific DNA motifs in their promoters . In plants such as tomato, BSD1 has been shown to regulate vegetative growth by directly activating genes like BRG1, binding to a specific motif (5′-CTTATTTC/A-3′) in its promoter . The regulation of BSD1 itself occurs primarily through protein-protein interactions and post-translational modifications, particularly ubiquitination by SINA proteins that leads to its proteasomal degradation .

What types of BSD1 antibodies are available for research?

Several types of BSD1 antibodies are available for research applications, with commercial monoclonal antibodies being particularly well-characterized. For example:

• Anti-BDH1 Mouse Monoclonal Antibody (clone 4B3): This is a primary, unconjugated monoclonal antibody produced in mouse that reacts with both human and mouse BDH1 (3-Hydroxybutyrate Dehydrogenase, Type 1), which is related to BSD1 research .

• Custom antibodies: Some research groups develop custom antibodies for specific epitopes of BSD1. For instance, researchers have successfully generated antibodies that can detect ubiquitinated forms of BSD1 in their experimental systems .

When selecting a BSD1 antibody, researchers should consider factors such as:

• Host species (mouse, rabbit, etc.)

• Clonality (monoclonal vs. polyclonal)

• Validated applications (Western blot, immunoprecipitation, ChIP, etc.)

• Species reactivity and cross-reactivity

• Recognition of specific protein states (native, denatured, post-translationally modified)

What experimental applications are BSD1 antibodies validated for?

BSD1 antibodies have been validated for multiple research applications:

• Western Blot Analysis: Anti-BSD1 antibodies can reliably detect BSD1 protein in cell and tissue lysates, allowing researchers to quantify protein levels across different experimental conditions .

• Immunoprecipitation (IP): BSD1 antibodies can effectively pull down BSD1 and its interaction partners from cell lysates, enabling the study of protein-protein interactions and post-translational modifications .

• Co-immunoprecipitation (Co-IP): Anti-BSD1 antibodies have been used successfully in co-IP experiments to identify and confirm binding partners like SINA proteins .

• Chromatin Immunoprecipitation (ChIP): For transcription factors like BSD1, ChIP assays using specific antibodies help identify DNA binding sites and target genes .

• ELISA: Some BSD1 antibodies are validated for enzyme-linked immunosorbent assays, allowing for quantitative detection of BSD1 in samples .

How can researchers study BSD1 protein-protein interactions effectively?

Studying BSD1 protein-protein interactions requires a combination of in vitro and in vivo approaches for comprehensive understanding:

In vitro approaches:

• Recombinant protein expression and purification: Express BSD1 and potential interacting proteins in E. coli with appropriate tags (MBP, His, HA) for purification. This approach was used successfully to study BSD1 interaction with SINA proteins .

• Pull-down assays: Use recombinant BSD1 protein (e.g., MBP-BSD1-HA) coupled to affinity matrix beads to capture potential binding partners. For example, researchers successfully demonstrated that "20 μg recombinant MBP-BSD1-HA protein was incubated with anti-HA Affinity Matrix in binding buffer, then used to pull down potential interacting proteins" .

In vivo approaches:

• Co-immunoprecipitation: Express epitope-tagged BSD1 (e.g., BSD1-Flag) together with tagged potential interaction partners (e.g., SINA1-6-HA) in plant systems using Agrobacterium-mediated transient expression. Immunoprecipitate with appropriate antibodies and detect interactions by Western blotting .

• Important consideration: When studying interactions with potential E3 ubiquitin ligases like SINA proteins, include proteasome inhibitors (e.g., MG132) in the experimental setup to prevent degradation of the target protein .

Verification of specificity:

• Always include appropriate controls (e.g., GFP-HA instead of SINA-HA) to confirm the specificity of interactions .

• Demonstrate binding specificity by showing that BSD1 interacts with some proteins (e.g., SINA1/2/3) but not others (e.g., SINA4/5/6) .

What methods are most effective for studying BSD1 ubiquitination?

BSD1 ubiquitination can be effectively studied using a combination of the following approaches:

In vitro ubiquitination assays:

• Express and purify recombinant BSD1 and potential E3 ligases (like SINA1)

• Perform in vitro ubiquitination reactions with E1 (e.g., AtUBA1), E2 (e.g., SlUBC12), and tagged ubiquitin (e.g., Flag-Ub)

• Detect ubiquitinated BSD1 by Western blotting using anti-BSD1 or anti-tag antibodies (smear pattern indicates poly-ubiquitination)

• Include appropriate controls:

  • Omit individual components (E1, E2, E3, ubiquitin) to verify the requirement of each

  • Include catalytically inactive E3 mutants (e.g., SINA1 C63S) to confirm E3 ligase dependency

Identification of ubiquitination sites:

• Perform in vitro ubiquitination of BSD1

• Separate proteins by SDS-PAGE

• Excise gel bands containing ubiquitinated BSD1

• Perform in-gel trypsin digestion

• Analyze by LC-MS/MS to identify peptides with ubiquitin remnant (GlyGly) modifications

• Verify identified sites by site-directed mutagenesis (e.g., K93R, K293R, K362R) and subsequent ubiquitination assays

In vivo ubiquitination:

• Co-express BSD1 with potential E3 ligases in plant cells

• Treat with proteasome inhibitors (e.g., MG132) to stabilize ubiquitinated forms

• Immunoprecipitate BSD1 and detect ubiquitination by Western blotting

• Compare with expression of BSD1 alone or with inactive E3 ligase mutants

How can the specificity of BSD1 antibodies be validated for research use?

Validating the specificity of BSD1 antibodies is crucial for ensuring reliable experimental results. A comprehensive validation approach should include:

Western blot analysis:

• Test the antibody on recombinant BSD1 protein to confirm recognition

• Compare signal detection in wild-type samples versus BSD1 knockout/knockdown samples

• Verify expected molecular weight (~40-45 kDa for BSD1, with higher molecular weight bands representing post-translationally modified forms)

• Assess cross-reactivity with related proteins by comparing against purified protein standards

Immunoprecipitation validation:

• Perform IP followed by Western blot (IP-WB) using the BSD1 antibody

• Confirm successful pull-down of BSD1 from complex protein mixtures

• Verify the absence of non-specific binding by including appropriate negative controls

• Consider reciprocal IP using different epitope tags when working with tagged BSD1 constructs

Peptide competition assay:

• Pre-incubate the BSD1 antibody with excess immunizing peptide

• Perform Western blot or IP with the neutralized antibody in parallel with untreated antibody

• Observe reduction or elimination of specific signal with peptide competition

Genetic validation:

• Compare antibody reactivity in wild-type versus BSD1-deficient systems (knockout, knockdown)

• Observe loss of specific signal in BSD1-deficient samples

• Confirm specificity by rescue experiments (reintroduction of BSD1 should restore antibody signal)

What techniques can identify BSD1 binding sites on DNA?

Identifying DNA binding sites for transcription factors like BSD1 requires a systematic approach combining multiple techniques:

Chromatin Immunoprecipitation (ChIP):

• Cross-link protein-DNA complexes in vivo using formaldehyde

• Isolate and shear chromatin

• Immunoprecipitate BSD1-bound DNA fragments using validated BSD1 antibodies

• Analyze immunoprecipitated DNA by PCR (ChIP-PCR) for known target regions or by sequencing (ChIP-seq) for genome-wide binding site identification

• Verify enrichment of potential binding sites compared to control regions or input DNA

Electrophoretic Mobility Shift Assay (EMSA):

• Generate recombinant BSD1 protein (e.g., His-BSD1)

• Prepare labeled DNA probes containing potential binding sites

• Perform binding reactions and analyze by native gel electrophoresis

• Observe mobility shift when BSD1 binds to DNA

• Confirm binding specificity through:

  • Competition with excess unlabeled probe

  • Testing mutated probe sequences

  • Systematic truncation/modification of probe sequences to identify minimal binding motif

Reporter gene assays:

• Clone promoter regions containing potential BSD1 binding sites upstream of reporter genes (e.g., GUS)

• Co-express the reporter construct with BSD1 in plant tissue

• Measure reporter activity to assess BSD1-mediated transcriptional activation

• Include promoter variants with mutated binding sites as controls

DNA binding site identification:
Through methodical analysis using these techniques, researchers identified that BSD1 binds to the BBS motif (5′-CTTATTTC/A-3′) in the promoter of the BRG1 gene. This was determined by creating progressively shortened oligonucleotide probes and testing BSD1 binding through EMSA, confirming specificity through competition assays and mutational analysis .

What are the best practices for BSD1 antibody storage and handling?

Proper storage and handling of BSD1 antibodies are essential for maintaining their activity and specificity:

Storage conditions:

• Store unconjugated antibodies at -20°C for long-term storage or at 4°C (refrigerated) for short-term use

• Avoid repeated freeze-thaw cycles by preparing single-use aliquots

• For shipping and transport, maintain antibodies on ice

Working solution preparation:

• Dilute antibodies in appropriate buffers based on the application (e.g., TBST with 1-5% BSA or non-fat milk for Western blot)

• For immunoprecipitation, use specialized IP buffers (20 mM HEPES-KOH, pH 7.9, 15% glycerol, 0.2 mM EDTA, 0.2% NP-40, 1 mM DTT, and 0.1 M NaCl)

• Prepare fresh dilutions for each experiment when possible

Quality control measures:

• Include positive controls (samples known to contain BSD1) in experiments

• Monitor for changes in antibody performance over time

• Document lot numbers and observe for lot-to-lot variations

• Periodically validate antibody specificity, especially with new experimental systems

How should researchers design experiments to study BSD1 degradation?

Designing experiments to study BSD1 degradation requires careful consideration of several factors:

Protein stability assays:

• Cycloheximide chase experiments:

  • Treat cells/tissues with cycloheximide to inhibit new protein synthesis

  • Collect samples at different time points (0, 1, 2, 4, 8 hours)

  • Analyze BSD1 protein levels by Western blot to determine degradation rate

  • Compare degradation rates between wild-type and systems with altered E3 ligase expression (e.g., SINA1 overexpression or knockdown)

• Proteasome inhibitor studies:

  • Treat samples with proteasome inhibitors (e.g., MG132, 10-50 μM)

  • Compare BSD1 levels with and without inhibitor treatment

  • Look for accumulation of higher molecular weight ubiquitinated forms when proteasome is inhibited

Co-expression studies:

• In plant expression systems:

  • Co-express BSD1 with potential regulators (e.g., SINA1) in Nicotiana benthamiana leaves via Agrobacterium-mediated transient expression

  • Include appropriate controls (inactive E3 ligase mutants, unrelated proteins like GFP)

  • Monitor BSD1 protein levels by Western blot

  • Include proteasome inhibitors to stabilize ubiquitinated forms

• Protoplast expression systems:

  • Use plant protoplasts for co-expression studies

  • Advantage: faster results and easier manipulation of conditions

  • Include treatments with or without proteasome inhibitors

  • Monitor BSD1 protein levels and look for ubiquitinated forms

Important controls and considerations:

• Include E3 ligase activity-deficient mutants (e.g., SINA1 C63S) as negative controls

• Consider the impact of epitope tags on protein stability and degradation

• Verify that observed effects are specific to the ubiquitin-proteasome pathway using different inhibitors

• Monitor both BSD1 protein levels and ubiquitination status simultaneously when possible

What purification methods yield high-quality BSD1 protein for functional studies?

Obtaining high-quality purified BSD1 protein is essential for various functional studies including protein-protein interaction assays, enzymatic assays, and structural studies:

Recommended expression and purification protocol:

• Expression system selection:

  • Use E. coli BL21 strain for heterologous expression of BSD1

  • Consider fusion tags to enhance solubility and facilitate purification:

    • MBP tag (maltose-binding protein) significantly improves BSD1 solubility

    • Add epitope tags (HA, FLAG, His) for detection and purification

• Purification workflow:

  • Express recombinant BSD1 protein in E. coli

  • Purify using affinity chromatography with the ÄKTA Start Protein Purification System (or similar)

  • Perform desalting and concentration using Amicon Centrifugal Filters with appropriate molecular weight cut-off

  • Determine protein concentration using Bradford Protein Assay

• Quality control checks:

  • Verify protein purity by SDS-PAGE

  • Confirm protein identity and integrity by Western blot using anti-BSD1 or anti-tag antibodies

  • Assess protein activity through functional assays (e.g., DNA binding for BSD1)

Important considerations:

• Buffer composition significantly affects protein stability and activity

• For BSD1 binding assays, recommended buffers include:

  • Binding buffer: 20 mM HEPES-KOH, pH 7.9, 15% glycerol, 0.2 mM EDTA, 0.2% NP-40, 1 mM DTT, and 0.1 M NaCl

  • Wash buffer: 20 mM HEPES-KOH, pH 7.9, 15% glycerol, 0.2 mM EDTA, 0.5% NP-40, 1 mM DTT, and 0.1 M NaCl

• Consider batch size limitations and scale-up requirements for specific applications

• Evaluate the impact of freeze-thaw cycles on protein activity; prepare single-use aliquots when possible

Why might BSD1 antibodies show weak or non-specific signals in Western blots?

Several factors can contribute to weak or non-specific signals when using BSD1 antibodies in Western blot applications:

Common causes of weak signals:

• Low BSD1 expression levels in samples:

  • Solution: Enrich for BSD1 by immunoprecipitation before Western blot

  • Consider using tissue or cell types known to express higher levels of BSD1

• Protein degradation during sample preparation:

  • Solution: Add protease inhibitors to lysis buffers

  • Process samples at 4°C and minimize handling time

  • Consider adding proteasome inhibitors if studying ubiquitinated forms

• Inefficient protein transfer:

  • Solution: Optimize transfer conditions for the molecular weight of BSD1

  • Consider using PVDF membranes which may better retain the protein

• Suboptimal antibody concentration:

  • Solution: Perform titration experiments to determine optimal primary antibody dilution

  • Extend primary antibody incubation time (overnight at 4°C)

Common causes of non-specific signals:

• Cross-reactivity with related proteins:

  • Solution: Use more specific monoclonal antibodies

  • Increase stringency of washing steps

  • Consider pre-adsorption of antibody with related proteins

• High background due to blocking issues:

  • Solution: Test different blocking reagents (BSA vs. non-fat milk)

  • Increase blocking time and concentration

• Detection of post-translationally modified BSD1:

  • Note: Higher molecular weight bands may represent ubiquitinated forms of BSD1

  • Solution: Include controls with and without treatment with deubiquitinating enzymes or phosphatases

• Antibody storage and quality issues:

  • Solution: Use fresh antibody aliquots

  • Validate antibody performance with positive control samples

How can researchers optimize co-immunoprecipitation protocols for BSD1 protein interactions?

Optimizing co-immunoprecipitation (co-IP) protocols for BSD1 protein interactions requires attention to several critical parameters:

Key optimization strategies:

• Buffer composition adjustments:

  • Test different lysis buffer formulations to balance protein extraction efficiency with preservation of interactions

  • For BSD1 interactions, successful buffers contain:

    • 20 mM HEPES-KOH, pH 7.9

    • 15% glycerol (stabilizes protein-protein interactions)

    • 0.2 mM EDTA

    • 0.2-0.5% NP-40 (mild detergent)

    • 1 mM DTT (reduces disulfide bonds)

    • 0.1-0.2 M NaCl (salt concentration affects interaction strength)

• Preventing protein degradation:

  • Add protease inhibitor cocktail to all buffers

  • When studying interactions with E3 ligases (like SINA1), include proteasome inhibitors (MG132, 50 μM) to prevent target degradation

  • Process samples at 4°C to minimize proteolysis

• Affinity matrix selection:

  • For tagged BSD1 (BSD1-Flag), use anti-FLAG antibody matrix

  • For tagged interaction partners (SINA-HA), use anti-HA Affinity Matrix

  • Consider magnetic beads for gentler handling and better recovery

• Reducing non-specific binding:

  • Pre-clear lysates with the affinity matrix alone

  • Block remaining active sites on beads with BSA (100 mg)

  • Increase stringency of wash steps incrementally while monitoring specific interactions

Critical controls:

• Input samples to verify protein expression

• Negative controls using unrelated tagged proteins (e.g., GFP-HA instead of SINA-HA)

• Reciprocal co-IPs (pull down with anti-BSD1 and probe for partners, then pull down partners and probe for BSD1)

• IgG control to assess non-specific binding to antibodies

By implementing these optimization strategies and controls, researchers can significantly improve the specificity and sensitivity of co-IP experiments for studying BSD1 protein interactions.

What are the emerging methods for studying BSD1 function in diverse experimental systems?

Recent technological advances have expanded the toolkit available for studying BSD1 function:

CRISPR/Cas9-mediated genome editing:

• Generate precise BSD1 knockout or knock-in models

• Create endogenously tagged BSD1 to study localization and interactions without overexpression artifacts

• Introduce specific mutations to study structure-function relationships (e.g., ubiquitination site mutants)

Proximity labeling approaches:

• BioID or TurboID fusions with BSD1 to identify proximal interacting proteins in living cells

• Allows identification of weak or transient interactions that may be missed by traditional co-IP

• Can reveal spatial organization of BSD1 protein complexes

Single-molecule techniques:

• Single-molecule pull-down (SiMPull) to study stoichiometry and composition of BSD1 complexes

• Single-molecule FRET to study conformational changes upon binding to partners or DNA

• These approaches provide insights into the dynamic behavior of individual molecules

High-throughput sequencing-based methods:

• ChIP-seq for genome-wide identification of BSD1 binding sites

• CUT&RUN or CUT&Tag as more sensitive alternatives to traditional ChIP

• RNA-seq in BSD1 mutant backgrounds to identify transcriptional targets

• Combined with bioinformatic analysis of motifs to identify new BSD1 binding sequences

Advanced imaging techniques:

• Super-resolution microscopy to study BSD1 localization and dynamics

• FRAP (Fluorescence Recovery After Photobleaching) to study mobility and binding dynamics

• Live-cell imaging of fluorescently tagged BSD1 to track localization changes in response to stimuli

How do researchers address contradictory findings in BSD1 ubiquitination studies?

Addressing contradictory findings in BSD1 ubiquitination studies requires careful experimental design and analytical approaches:

Common sources of contradictions:

• Complexity of ubiquitination sites:
  Research shows that while LC-MS/MS identified three specific lysine residues (K93, K293, K362) as BSD1 ubiquitination sites, mutation of these residues did not completely prevent ubiquitination . This apparent contradiction can be explained by:

  • Conformational changes caused by K-to-R mutations exposing alternate lysine residues for ubiquitination

  • Potential ubiquitination at multiple redundant sites

  • Different E3 ligases potentially targeting different lysine residues

• Experimental system variations:
  Contradictions may arise when comparing in vitro versus in vivo systems:

  • In vitro systems may allow non-physiological interactions due to high protein concentrations

  • In vivo systems may have additional regulatory factors not present in reconstituted systems

  • Different cell types or species may show different ubiquitination patterns for BSD1

Approaches to resolve contradictions:

• Comprehensive mutagenesis:

  • Create a panel of BSD1 mutants with different combinations of lysine mutations

  • Analyze ubiquitination patterns in parallel using standardized protocols

  • Compare ubiquitination in vitro and in vivo for each mutant

• Structural analysis:

  • Determine how K-to-R mutations affect BSD1 protein folding and conformation

  • Assess whether mutations expose additional lysine residues that can serve as alternative ubiquitination sites

  • Use computational modeling to predict structural changes

• Temporal and context-dependent analysis:

  • Investigate whether ubiquitination patterns change over time or under different conditions

  • Determine if different E3 ligases (beyond SINA1) target different lysine residues

  • Examine cell type-specific or developmental stage-specific differences in BSD1 ubiquitination

• Comparative analysis across species:

  • Compare BSD1 ubiquitination in different model organisms

  • Identify conserved versus species-specific ubiquitination sites

By systematically addressing these factors, researchers can reconcile contradictory findings and develop a more comprehensive understanding of BSD1 ubiquitination mechanisms.

Data Table: BSD1 Antibody Characteristics and Applications